-- U.S. RESEARCH ROUNDUP- Legacy Reserves, Cubist Pharmaceuticals
-- 
-- Tue Dec 09, 2014 12:22AM EST
-- None



Dec 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Navios Maritime and Mid-Con Energy, on Tuesday.

HIGHLIGHTS * Oil & Gas: Wells Fargo cuts Legacy Reserves <LGCY.O> to market perform [ID:nWNAB05GAK] * Cubist Pharmaceuticals <CBST.O>: SunTrust Robinson cuts to neutral; raises target to $102   Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.* Athenahealth Inc <ATHN.O>: Jefferies cuts price target to $114 from $135; rating hold * Bluebird Bio <BLUE.O>: SunTrust Robinson raises target price to $115 from $57; rating buy * Breitburn Energy <BBEP.O>: Wells Fargo cuts to market perform from outperform * Cubist Pharmaceuticals <CBST.O>: SunTrust Robinson cuts to neutral from buy * Cubist Pharmaceuticals <CBST.O>: SunTrust Robinson raises price target to $102 from $96 * Edwards Lifesciences <EW.N>: Canaccord raises target price to $153 from $125; rating buy * Edwards Lifesciences <EW.N>: BMO raises target to $135 from $100; rating market perform * Humana <HUM.N>: Raymond James raises price target to $151 from $140; rating outperform * Legacy Reserves <LGCY.O>: Wells Fargo cuts to market perform from outperform * Lumber Liquidators <LL.N>: Canaccord Genuity raises target to $60 from $51; rating hold * Mid-Con Energy Partners <MCEP.O>: Wells Fargo cuts to market perform from outperform * Navios Maritime Midstream Partners <NAP.N>: Wells Fargo starts with market perform rating * PPG Industries <PPG.N>: Susquehanna raises target price to $262 from $240; rating positive * Sage Therapeutics <SAGE.O>: Leerink raises target price to $54 from $46; rating outperform * Valero <VLO.N>: Oppenheimer cuts target price to $60 from $65; rating outperform * Wesco Aircraft <WAIR.N>: Jefferies cuts price target to $17 from $20; rating hold * ZS Pharma <ZSPH.O>: BMO raises target price to $54 from $45; rating outperform